Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Current evidence and future directions for prophylactic anticoagulation therapy after severe spontaneous intracerebral hemorrhage: a narrative review.Journal of intensive medicine · 2026
   Review
2. Preoperative neutrophil-to-lymphocyte ratio and postoperative deep vein thrombosis after tibial plateau fracture: a retrospective analysis of a prospectively collected cohort.BMC musculoskeletal disorders · 2026
   Article
3. The role of ginkgo leaf extract and dipyridamole adjuvant treatment for reduction of lower limb deep vein thrombosis after proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fracture.Frontiers in pharmacology · 2026
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as